WO2007014278A3 - B-cell reduction using cd37-specific and cd20-specific binding molecules - Google Patents

B-cell reduction using cd37-specific and cd20-specific binding molecules Download PDF

Info

Publication number
WO2007014278A3
WO2007014278A3 PCT/US2006/029038 US2006029038W WO2007014278A3 WO 2007014278 A3 WO2007014278 A3 WO 2007014278A3 US 2006029038 W US2006029038 W US 2006029038W WO 2007014278 A3 WO2007014278 A3 WO 2007014278A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding molecules
specific binding
specific
cell reduction
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/029038
Other languages
French (fr)
Other versions
WO2007014278A2 (en
Inventor
Laura Sue Grosmaire
Martha Susan Hayden-Ledbetter
Jeffrey A Ledbetter
Peter Armstrong Thompson
Sandy Alexander Simon
William Brady
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trubion Pharmaceuticals Inc
Original Assignee
Trubion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37683960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007014278(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2006272555A priority Critical patent/AU2006272555B2/en
Priority to UAA200802255A priority patent/UA97469C2/en
Priority to EP06788565.7A priority patent/EP1912675B1/en
Priority to NZ594275A priority patent/NZ594275A/en
Priority to SI200631765T priority patent/SI1912675T1/en
Priority to HRP20140338TT priority patent/HRP20140338T1/en
Priority to HK08111578.9A priority patent/HK1115820B/en
Priority to RS20140232A priority patent/RS53318B/en
Priority to HK09102857.9A priority patent/HK1125288B/en
Priority to PL06788565T priority patent/PL1912675T3/en
Priority to KR1020087003703A priority patent/KR101251157B1/en
Priority to CA2616395A priority patent/CA2616395C/en
Priority to BRPI0614184A priority patent/BRPI0614184A8/en
Priority to JP2008524109A priority patent/JP5740076B2/en
Priority to ES06788565.7T priority patent/ES2460517T3/en
Priority to DK06788565.7T priority patent/DK1912675T3/en
Priority to NZ564764A priority patent/NZ564764A/en
Priority to CN200680027227.9A priority patent/CN101282745B/en
Application filed by Trubion Pharmaceuticals Inc filed Critical Trubion Pharmaceuticals Inc
Publication of WO2007014278A2 publication Critical patent/WO2007014278A2/en
Publication of WO2007014278A3 publication Critical patent/WO2007014278A3/en
Priority to IL188345A priority patent/IL188345A/en
Priority to NO20080217A priority patent/NO20080217L/en
Priority to ZA2008/00692A priority patent/ZA200800692B/en
Anticipated expiration legal-status Critical
Priority to IL237881A priority patent/IL237881A0/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)

Abstract

The present application generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The application further provides materials and methods for application treatment of diseases involving aberrant B-cell activity. In addition, the application provides humanized CD37-specific binding molecules.
PCT/US2006/029038 2005-07-25 2006-07-25 B-cell reduction using cd37-specific and cd20-specific binding molecules Ceased WO2007014278A2 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
UAA200802255A UA97469C2 (en) 2005-07-25 2006-07-25 Humanized cd37-specific binding immunoglobulin molecule
BRPI0614184A BRPI0614184A8 (en) 2005-07-25 2006-07-25 B CELL REDUCTION WITH THE USE OF CD37-SPECIFIC AND CD20-SPECIFIC BINDERS
EP06788565.7A EP1912675B1 (en) 2005-07-25 2006-07-25 B-cell reduction using cd37-specific and cd20-specific binding molecules
NZ594275A NZ594275A (en) 2005-07-25 2006-07-25 B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
SI200631765T SI1912675T1 (en) 2005-07-25 2006-07-25 B-cell reduction using cd37-specific and cd20-specific binding molecules
HRP20140338TT HRP20140338T1 (en) 2005-07-25 2006-07-25 B-cell reduction using cd37-specific and cd20-specific binding molecules
HK08111578.9A HK1115820B (en) 2005-07-25 2006-07-25 B-cell reduction using cd37-specific and cd20-specific binding molecules
RS20140232A RS53318B (en) 2005-07-25 2006-07-25 B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
HK09102857.9A HK1125288B (en) 2005-07-25 2006-07-25 B-cell reduction using cd37-specific and cd20-specific binding molecules
PL06788565T PL1912675T3 (en) 2005-07-25 2006-07-25 B-cell reduction using cd37-specific and cd20-specific binding molecules
KR1020087003703A KR101251157B1 (en) 2005-07-25 2006-07-25 B-cell reduction using cd37-specific and cd20-specific binding molecules
ES06788565.7T ES2460517T3 (en) 2005-07-25 2006-07-25 Reduction of b cells by using cd37 specific binding and cd20 specific binding molecules
JP2008524109A JP5740076B2 (en) 2005-07-25 2006-07-25 Reduction of B cells using CD37-specific and CD20-specific binding molecules
AU2006272555A AU2006272555B2 (en) 2005-07-25 2006-07-25 B-cell reduction using CD37-specific and CD20-specific binding molecules
CA2616395A CA2616395C (en) 2005-07-25 2006-07-25 B-cell reduction using cd37-specific and cd20-specific binding molecules
DK06788565.7T DK1912675T3 (en) 2005-07-25 2006-07-25 B-cell reduction using specific and cd37-cd20-specific binding molecules
NZ564764A NZ564764A (en) 2005-07-25 2006-07-25 B-cell reduction using CD37-specific and CD20-specific binding molecules
CN200680027227.9A CN101282745B (en) 2005-07-25 2006-07-25 B-cell reduction with CD37-specific and CD20-specific binding molecules
IL188345A IL188345A (en) 2005-07-25 2007-12-23 Cd37 specific binding protein
NO20080217A NO20080217L (en) 2005-07-25 2008-01-14 B-cell reduction using CD20-specific binding molecules
ZA2008/00692A ZA200800692B (en) 2005-07-25 2008-01-23 B-cell reduction using cd37-specific and cd20-specific binding molecules
IL237881A IL237881A0 (en) 2005-07-25 2015-03-22 B-cell reduction using cd37-specific and cd20-specific binding molecules

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70249905P 2005-07-25 2005-07-25
US60/702,499 2005-07-25
US80059506P 2006-05-16 2006-05-16
US60/800,595 2006-05-16

Publications (2)

Publication Number Publication Date
WO2007014278A2 WO2007014278A2 (en) 2007-02-01
WO2007014278A3 true WO2007014278A3 (en) 2007-08-30

Family

ID=37683960

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/029038 Ceased WO2007014278A2 (en) 2005-07-25 2006-07-25 B-cell reduction using cd37-specific and cd20-specific binding molecules

Country Status (28)

Country Link
US (7) US10307481B2 (en)
EP (4) EP2295080A3 (en)
JP (3) JP5740076B2 (en)
KR (1) KR101251157B1 (en)
CN (2) CN101282745B (en)
AU (1) AU2006272555B2 (en)
BR (1) BRPI0614184A8 (en)
CA (1) CA2616395C (en)
CO (1) CO6160337A2 (en)
CR (1) CR9761A (en)
DK (2) DK2298815T3 (en)
EC (1) ECSP088133A (en)
ES (2) ES2539250T3 (en)
HR (2) HRP20140338T1 (en)
HU (1) HUE026303T2 (en)
IL (2) IL188345A (en)
NI (1) NI200800032A (en)
NO (1) NO20080217L (en)
NZ (3) NZ594275A (en)
PL (2) PL2298815T3 (en)
PT (2) PT1912675E (en)
RS (2) RS53318B (en)
RU (1) RU2423381C2 (en)
SG (2) SG155912A1 (en)
SI (2) SI1912675T1 (en)
UA (1) UA97469C2 (en)
WO (1) WO2007014278A2 (en)
ZA (1) ZA200800692B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12577316B2 (en) 2017-03-31 2026-03-17 Genmab Holding B.V. Methods of use of anti-CD37 antibodies, monoclonal anti-CD37 antibodies

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2003037314A2 (en) 2001-11-01 2003-05-08 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
EP2295080A3 (en) 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
EP1986640A1 (en) * 2006-02-09 2008-11-05 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment by using e09 and propylene glycol
EP1996716B1 (en) 2006-03-20 2011-05-11 The Regents of the University of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
CN105837690A (en) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 Single-chain multivalent binding proteins with effector function
US7846434B2 (en) 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
CA2663536A1 (en) * 2006-10-24 2008-05-02 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
CN101842389A (en) * 2007-06-12 2010-09-22 惠氏有限责任公司 Anti-cd20 therapeutic compositions and methods
PE20140196A1 (en) * 2007-08-09 2014-03-19 Boehringer Ingelheim Int ANTI-CD37 ANTIBODIES
US8940298B2 (en) * 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
CN101874042B9 (en) 2007-09-26 2019-01-01 中外制药株式会社 Method for changing isoelectric point of antibody by using amino acid substitution of CDR
CN101939425B (en) 2007-09-26 2014-05-14 中外制药株式会社 Anti-IL-6 receptor antibody
WO2009046294A2 (en) * 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
CN101945667A (en) * 2007-12-21 2011-01-12 健泰科生物技术公司 Therapy of rituximab-refractory rheumatoid arthritis patients
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
PT2132228E (en) * 2008-04-11 2011-10-11 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
WO2009134738A1 (en) * 2008-04-29 2009-11-05 Genentech, Inc. Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
WO2010057047A1 (en) * 2008-11-13 2010-05-20 Trubion Pharmaceutics, Inc. Cd37 immunotherapeutic combination therapies and uses thereof
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP3495000A1 (en) * 2009-02-17 2019-06-12 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
DK3202898T3 (en) 2009-11-02 2019-01-14 Univ Washington THERAPEUTIC NUCLEASE COMPOSITIONS AND PROCEDURES
MX337600B (en) 2009-12-02 2016-03-11 Imaginab Inc J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use.
NO331080B1 (en) 2010-01-29 2011-09-26 Nordic Nanovector As Radioimmune conjugates, pharmaceutical compositions and kits comprising the same and their use
US9260529B2 (en) 2010-02-24 2016-02-16 The University Of Washington Through Its Center For Commercialization Molecules that bind CD180, compositions and methods of use
MX338932B (en) * 2010-03-12 2016-05-06 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof.
US20120189618A1 (en) * 2010-07-16 2012-07-26 Boehringer Ingelheim International Gmbh Superior efficacy of cd37 antibodies in cll blood samples
CA2806252C (en) 2010-07-29 2019-05-14 Xencor, Inc. Antibodies with modified isoelectric points
CN105999293B (en) 2011-04-01 2019-07-23 德彪发姆国际有限公司 CD37 binding molecule and its immunoconjugates
SG194510A1 (en) 2011-04-22 2013-12-30 Emergent Product Dev Seattle Prostate-specific membrane antigen binding proteins and related compositionsand methods
PH12013502441B1 (en) 2011-04-29 2019-02-08 Univ Washington Therapeutic nuclease compositions and methods
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
KR20140103140A (en) * 2011-12-13 2014-08-25 노르딕 나노벡터 에이에스 Chimeric Therapeutic Anti-CD37 Antibody HH1
WO2013160396A1 (en) * 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
JP2015517512A (en) * 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combined use of CD37 antibody with additional drugs
US8992915B2 (en) 2012-05-16 2015-03-31 Boehringer Ingelheim International Gmbh Combination of CD37 antibodies with ICE
MX2015008190A (en) * 2012-12-21 2016-03-31 Univ California Tspan 33 is a candidate for antibody targeted therapy for the treatment of b cell hodgkin lymphomas.
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
CA2898100C (en) 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
CA2897987A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10228452B2 (en) 2013-06-07 2019-03-12 Hand Held Products, Inc. Method of error correction for 3D imaging device
BR112015030457A2 (en) * 2013-06-07 2017-08-22 Nordic Nanovector As METHOD TO POSITIVELY REGULATE ANTIGEN EXPRESSION
HK1225621A1 (en) 2013-08-01 2017-09-15 Agensys, Inc. Antibody drug conjugates (adc) that bind to cd37 proteins
WO2015066304A1 (en) * 2013-10-30 2015-05-07 Trans Union Llc Systems and methods for measuring effectiveness of marketing and advertising campaigns
SI3063275T1 (en) 2013-10-31 2020-02-28 Resolve Therapeutics, Llc Therapeutic nuclease-albumin fusions and methods
JP6775422B2 (en) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Bispecific antibody that binds to CD38 and CD3
JP6600651B2 (en) * 2014-06-16 2019-10-30 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ Myeloma treatment
JP2017536830A (en) 2014-11-26 2017-12-14 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Heterodimeric antibodies that bind to CD3 and CD38
SG11201704283PA (en) 2014-11-26 2017-06-29 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
UA125496C2 (en) * 2015-06-08 2022-04-13 Дебіофарм Інтернаціонал, С.А. Method of treating a patient with b-cell cancer with an immunoconjugate that binds to cd37 together with an antibody that binds to cd20
KR20250008141A (en) 2015-08-07 2025-01-14 이미지냅 인코포레이티드 Antigen binding constructs to target molecules
AU2016316758B2 (en) 2015-08-28 2023-02-02 Debiopharm International, S.A. Antibodies and assays for detection of CD37
KR102784293B1 (en) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 CD3 binding polypeptide
JP7058219B2 (en) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Heterodimer antibody that binds to CD3 and PSMA
US20170174781A1 (en) * 2015-12-22 2017-06-22 Regeneron Pharmaceuticals, Inc. Bispecific Anti-CD20/Anti-CD3 Antibodies to Treat Acute Lymphoblastic Leukemia
MA45255A (en) 2016-06-14 2019-04-17 Xencor Inc BISPECIFIC CONTROL POINT INHIBITORS ANTIBODIES
KR20190020341A (en) 2016-06-28 2019-02-28 젠코어 인코포레이티드 Heterozygous antibodies that bind to somatostatin receptor 2
AU2017290389B2 (en) 2016-07-01 2024-09-26 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
BR112019007281A2 (en) 2016-10-14 2019-07-09 Xencor Inc heterodimeric protein, nucleic acid and expression vector compositions, expression vector, host cell, and methods for producing heterodimeric protein and for treating cancer in a patient
WO2018083633A1 (en) 2016-11-02 2018-05-11 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP3559044A4 (en) * 2016-12-23 2020-12-02 REMD Biotherapeutics, Inc. Immunotherapy using antibodies that bind programmed death 1 (pd-1)
WO2018132506A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
US10947295B2 (en) 2017-08-22 2021-03-16 Sanabio, Llc Heterodimers of soluble interferon receptors and uses thereof
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
AU2018390418B2 (en) 2017-12-19 2023-12-21 Xencor, Inc. Engineered IL-2 Fc fusion proteins
AU2019247415A1 (en) 2018-04-04 2020-10-22 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CA3097593A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
JP2021520829A (en) 2018-04-18 2021-08-26 ゼンコア インコーポレイテッド TIM-3 targeted heterodimer fusion protein containing IL-15 / IL-15RA Fc fusion protein and TIM-3 antigen binding domain
ES2714952B2 (en) * 2018-05-18 2020-07-10 Productos Agrovin S A PROCEDURE AND EQUIPMENT FOR STORING DURING HARVEST MACERATION
CA3101790A1 (en) 2018-05-30 2019-12-05 Debiopharm International, S.A. Anti-cd37 immunoconjugate dosing regimens
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
JP7611705B2 (en) * 2018-06-22 2025-01-10 ザ ジェネラル ホスピタル コーポレイション Chimeric antigen receptor targeting CD37 and CD19
WO2020004337A1 (en) * 2018-06-27 2020-01-02 国立大学法人名古屋大学 Cd37-specific chimeric antigen receptor
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2020180726A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
US12358987B2 (en) * 2019-07-08 2025-07-15 Nanjing GenScript Biotech Co., Ltd. Anti-CD47/anti-PD-1 bispecific antibody, preparation method and use thereof
CN121197633A (en) 2019-12-13 2025-12-26 比特比德科有限责任公司 Ingestible device for delivering therapeutic agents to the gastrointestinal tract
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CN113980130B (en) * 2020-07-27 2023-07-21 湖南远泰生物技术有限公司 Humanized CD37 and bispecific CD19-humanized CD37 CAR-T cells
KR20230156079A (en) 2021-03-09 2023-11-13 젠코어 인코포레이티드 Heterodimeric antibody binding to CD3 and CLDN6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
WO2023049732A1 (en) 2021-09-21 2023-03-30 Qilu Puget Sound Biotherapeutics Corporation HETERODIMERIC Fc FOR MAKING FUSION PROTEINS AND BISPECIFIC ANTIBODIES
MX2024004048A (en) 2021-10-18 2024-04-25 Daiichi Sankyo Co Ltd Anti-cd37 antibody-drug conjugate.
WO2023133488A1 (en) * 2022-01-06 2023-07-13 The General Hospital Corporation Methods of cell ablation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050136049A1 (en) * 2001-01-17 2005-06-23 Ledbetter Jeffrey A. Binding constructs and methods for use thereof

Family Cites Families (417)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3927193A (en) 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4460559A (en) 1980-03-03 1984-07-17 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4460561A (en) 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4468457A (en) 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4818709A (en) 1983-01-21 1989-04-04 Primus Frederick J CEA-family antigens, Anti-CEA antibodies and CEA immunoassay
US4460459A (en) 1983-02-16 1984-07-17 Anschutz Mining Corporation Sequential flotation of sulfide ores
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4624846A (en) 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4782840A (en) 1984-03-02 1988-11-08 Neoprobe Corporation Method for locating, differentiating, and removing neoplasms
US4906562A (en) * 1984-12-21 1990-03-06 Oncogen Monocolonal antibodies and antigen for human non-small cell lung carcinomas
US4935495A (en) * 1984-12-21 1990-06-19 Oncogen Monoclonal antibodies to the L6 glycolipid antigenic determinant found on human non-small cell lung carcinomas
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US5955315A (en) * 1985-11-19 1999-09-21 Schering Corporation Nucleic acids encoding human interleukin-4
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
US4932412A (en) 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5892019A (en) * 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JP3095168B2 (en) 1988-02-05 2000-10-03 エル． モリソン，シェリー Antibodies with domain-denaturing constants
FI102355B1 (en) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Process for Preparation of Anthracycline Immunoconjugates with a Linking Link
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
WO1989008114A1 (en) 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US6352694B1 (en) * 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
CA2006408A1 (en) 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
US5217713A (en) 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5098833A (en) * 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5897861A (en) 1989-06-29 1999-04-27 Medarex, Inc. Bispecific reagents for AIDS therapy
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5980896A (en) 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
DE69030579T2 (en) 1989-09-20 1997-11-13 Abbott Lab METHOD FOR PRODUCING FUSION PROTEINS
US6018031A (en) 1989-10-20 2000-01-25 Trustees Of Dartmouth College Binding agents specific for IgA receptor
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
SG70982A1 (en) 1990-01-23 2000-03-21 Tanox Biosystems Inc Extracellular segments of human and immunoglobulin anchoring peptides and antibodies specific therefor
JPH07507440A (en) 1990-03-02 1995-08-24 レプリゲン・コーポレーション Antibody constructs with increased binding affinity
US20030219446A1 (en) 1990-03-26 2003-11-27 Bristol-Myers Squibb Company Ligand for CD28 receptor on B cells and methods
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
GB9009106D0 (en) 1990-04-23 1990-06-20 3I Res Expl Ltd Processes and intermediates for synthetic antibody derivatives
CA2086325C (en) 1990-07-02 2010-10-05 Peter S. Linsley Ligand for cd28 receptor on b cells and methods
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5130307A (en) 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
EP0585257A4 (en) 1991-03-28 1995-02-22 Univ Minnesota FOR NATURAL KILLER CELLS SPECIFIC DNA AND AMINO ACID SEQUENCE.
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
JPH06508133A (en) 1991-05-31 1994-09-14 ジェネンテク，インコーポレイテッド Treatment of HIV-associated immune thrombocytopenic purpura
DE4118120A1 (en) 1991-06-03 1992-12-10 Behringwerke Ag TETRAVALENT BISPECIFIC RECEPTORS, THEIR PRODUCTION AND USE
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
EP0606217B2 (en) 1991-06-27 2008-12-03 Bristol-Myers Squibb Company Ctl4a receptor, fusion proteins containing it and uses thereof
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
ATE132742T1 (en) 1991-08-16 1996-01-15 Vical Inc COMPOSITION AND METHOD FOR TREATING CYSTIC FIBROSIS
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US6027725A (en) * 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
DE69233528T2 (en) 1991-11-25 2006-03-16 Enzon, Inc. Process for the preparation of multivalent antigen-binding proteins
PT1696031E (en) 1991-12-02 2010-06-25 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
IL104684A0 (en) 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
JPH07507689A (en) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Specific tissue targeting methods and compositions
WO1993025698A1 (en) 1992-06-10 1993-12-23 The United States Government As Represented By The Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
DK0586002T3 (en) 1992-08-18 2000-06-19 Centro Inmunologia Molecular Monoclonal antibodies that recognize the epidermal growth factor receptor, its cells and methods, and preparations thereof
PT1621554E (en) 1992-08-21 2009-07-13 Univ Bruxelles IMMUNOGLOBTAINES OF LIGHT CHAINS
ZA936260B (en) 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
ZA937553B (en) 1992-10-12 1994-05-03 Agen Ltd Clot directed anticoagulant process for making same and methods of use
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
DE69303494T2 (en) 1992-11-13 1997-01-16 Idec Pharma Corp THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES AGAINST HUMAN B LYMPHOCYTIC LIMITED DIFFERENTIATION ANTIQUES FOR THE TREATMENT OF B CELL LYMPHOMA
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
JP3720353B2 (en) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their production and use
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US5773253A (en) * 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6482919B2 (en) 1993-02-01 2002-11-19 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5597707A (en) * 1993-04-15 1997-01-28 Bristol-Myers Squibb Company Tumor associated antigen recognized by the murine monoclonal antibody L6, its oligonucleotide sequence and methods for their use
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
WO1995006666A1 (en) 1993-09-02 1995-03-09 Trustees Of Dartmouth College Anti-gp39 antibodies and uses therefor
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
GB9412166D0 (en) 1993-09-22 1994-08-10 Medical Res Council Retargetting antibodies
EP0720624B1 (en) 1993-09-22 1998-11-25 Medical Research Council Retargeting antibodies
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
PT734389E (en) 1993-12-17 2000-09-29 Novartis Ag US RAPAMICINE DERIVATIVES AS IMMUNOSUPRESSORS
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US6380369B1 (en) 1994-01-27 2002-04-30 Human Genome Sciences, Inc. Human DNA mismatch repair proteins
WO1995021258A1 (en) * 1994-02-01 1995-08-10 United States Of America, Represented By The Secretary, Department Of Health And Human Services Fusion proteins that include antibody and nonantibody portions
CA2183268C (en) 1994-03-07 2001-05-15 Edward D. Ball Bispecific molecules having clinical utilities
ES2191702T3 (en) 1994-03-17 2003-09-16 Merck Patent Gmbh FV MONOCATENARY ANTI-EGFR AND ANTI-EGFR ANTIBODIES.
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
KR100373813B1 (en) 1994-05-02 2003-10-08 베른트 그로너 Bifunctional protein, its manufacture and use
US5945273A (en) 1997-06-03 1999-08-31 Human Genome Sciences, Inc. Human oxalyl-coa decarboxylase
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5888773A (en) 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
PT807183E (en) 1994-08-26 2001-05-31 Aventis Pharma Gmbh GENETIC THERAPY OF DISEASES INDUCED BY THE IMMUNE SYSTEM WITH THE ASSISTANCE OF A REGULATORY SUBSTANCE OF THE CELL SPECIFIC CELL CYCLE
US6380169B1 (en) 1994-08-31 2002-04-30 Isis Pharmaceuticals, Inc. Metal complex containing oligonucleoside cleavage compounds and therapies
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
CZ292233B6 (en) 1995-06-09 2003-08-13 Novartis Ag Rapamycin derivatives and their use as medicaments
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US5866330A (en) 1995-09-12 1999-02-02 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
ATE247488T1 (en) * 1995-10-13 2003-09-15 Us Gov Health & Human Serv IMMUNOTOXIN CONTAINING A DISULFIDE STABILIZED ANTIBODY FRAGMENT
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6379966B2 (en) 1999-02-26 2002-04-30 Mirus Corporation Intravascular delivery of non-viral nucleic acid
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
GB2310894A (en) 1996-03-06 1997-09-10 Clive William Efford Multi-engine drive unit
EP1186300A1 (en) 1996-03-20 2002-03-13 Bristol-Myers Squibb Company Pharmaceutical compositions useful for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways
AU710998B2 (en) * 1996-03-20 1999-10-07 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4 /CD28/B7 pathways and compositions for use therewith
DE19613691A1 (en) 1996-04-05 1997-10-09 Boehringer Ingelheim Int Medicines for the treatment of tumor diseases
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
WO1998002540A1 (en) * 1996-07-12 1998-01-22 Genentech, Inc. Chimeric heteromultimer adhesins
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
EP0938506B1 (en) 1996-07-16 2003-11-05 Plückthun, Andreas, Prof. Dr. Immunoglobulin superfamily domains and fragments with increased solubility
US5846948A (en) 1996-08-30 1998-12-08 Arch Development Corporation Herpes simplex virus ORF P is a repressor of viral protein synthesis
GB9618477D0 (en) 1996-09-04 1996-10-16 Univ Leeds Gene therapy
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US5972361A (en) 1996-10-25 1999-10-26 The Procter & Gamble Company Cleansing products
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
DE19651443A1 (en) 1996-12-11 1998-06-18 Hoechst Ag Self-reinforcing, pharmacologically controllable expression systems
KR19980066046A (en) 1997-01-18 1998-10-15 정용훈 High-CTLA4-Ig fusion protein
EP0860445A1 (en) 1997-02-18 1998-08-26 Hoechst Aktiengesellschaft New nucleotide sequences for the cell cycle regulated expression of structural genes
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
ATE241993T1 (en) 1997-03-11 2003-06-15 Aeterna Lab Inc PREPARATIONS FOR TUMOR TREATMENT CONTAINING SHARK CARTIL EXTRACTS AND ANTINEOPLASTIC AGENTS
CA2284211A1 (en) 1997-03-20 1998-09-24 University Of Washington Solvent for biopolymer synthesis, solvent microdroplets and methods of use
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
WO1999002567A2 (en) 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
US6383746B1 (en) 1997-10-23 2002-05-07 The United States Of America As Represented By The Department Of Health And Human Services Functional promoter for CCR5
DE69840412D1 (en) 1997-10-31 2009-02-12 Genentech Inc METHODS AND COMPOSITIONS CONTAINING GLYCOPROTEIN GLYCOR FORMS
US6383811B2 (en) 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
PT1049787E (en) 1998-01-23 2005-04-29 Vlaams Interuniv Inst Biotech DERIVATIVES OF MULTIPROPOSTY ANTIBODIES
CN1316910A (en) 1998-02-19 2001-10-10 埃克斯西特治疗公司 Compositions and methods for modulating lymphocyte activation
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
CN1204147C (en) 1998-02-25 2005-06-01 利思进药品公司 Methods of increasing the circulating half-life of antibody-based fusion proteins
US6383481B1 (en) 1998-03-30 2002-05-07 Japan Immunoresearch Laboratories Co., Ltd. Method for transplantation of hemopoietic stem cells
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
WO1999054484A1 (en) * 1998-04-20 1999-10-28 The Regents Of The University Of California Modified immunoglobulin molecules and methods for use thereof
EP1073721B1 (en) 1998-04-22 2005-08-31 Genvec, Inc. Efficient purification of adenovirus
GB9809280D0 (en) 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
DE19819846B4 (en) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalent antibody constructs
WO1999061630A2 (en) 1998-05-26 1999-12-02 Regeneron Pharmaceuticals, Inc. Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
US7052872B1 (en) 1999-06-22 2006-05-30 Immunomedics, Inc. Bi-specific antibodies for pre-targeting diagnosis and therapy
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
AU750414B2 (en) 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
WO2000006605A2 (en) 1998-07-28 2000-02-10 Micromet Ag Heterominibodies
PL195870B1 (en) 1998-08-11 2007-11-30 Biogen Idec Inc Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US6383794B1 (en) 1998-08-24 2002-05-07 Uab Research Foundation Methods of producing high titer recombinant adeno-associated virus
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
AU2472400A (en) * 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6197294B1 (en) 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
WO2000027885A1 (en) 1998-11-05 2000-05-18 Kyowa Hakko Kogyo Co., Ltd. Novel chimeric polypeptide
DK1616572T3 (en) 1998-11-09 2010-12-06 Biogen Idec Inc Chimeric anti-CD20 antibody, rituxane, for use in the treatment of chronic lymphocytic leukemia
HK1041811A1 (en) 1998-11-09 2002-07-26 Idec药物公司 Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants
US6380371B1 (en) 1998-12-10 2002-04-30 The Regents Of The University Of California Endoglycan: a novel protein having selectin ligand and chemokine presentation activity
KR100940380B1 (en) 1999-01-15 2010-02-02 제넨테크, 인크. Polypeptide Variants with Altered Effector Function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
JP2002536968A (en) 1999-01-29 2002-11-05 イムクローン システムズ インコーポレイティド Antibodies specific for KDR and uses thereof
EP1035172A3 (en) 1999-03-12 2002-11-27 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
US6383753B1 (en) 1999-03-31 2002-05-07 Regents Of The University Of Michigan Yeast mammalian regulators of cell proliferation
AU4476600A (en) 1999-04-22 2000-11-10 Vanderbilt University Polymeric encapsulation system promoting angiogenesis
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
US6358596B1 (en) * 1999-04-27 2002-03-19 The Standard Register Company Multi-functional transparent secure marks
ATE311199T1 (en) 1999-05-07 2005-12-15 Genentech Inc TREATMENT OF AUTOIMMUNE DISEASES WITH ANTAGONISTS THAT BIND SURFACE MARKERS OF B CELLS
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
KR20020018197A (en) 1999-05-19 2002-03-07 추후보정 EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS
EP1194167B1 (en) 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
ITMI991299A1 (en) 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche USE OF ANTIBODIES AGAINST SURFACE ANTIGENS FOR THE TREATMENT OF DISEASE TRANSPLANT AGAINST GUESTS
US6380382B1 (en) 1999-06-30 2002-04-30 Millennium Pharmaceuticals, Inc. Gene encoding a protein having diagnostic, preventive, therapeutic, and other uses
DE19930748C2 (en) 1999-07-02 2001-05-17 Infineon Technologies Ag Method for producing EEPROM and DRAM trench memory cell areas on a chip
AU778863B2 (en) 1999-07-12 2004-12-23 Genentech Inc. Blocking immune response to a foreign antigen using an antagonist which binds to CD20
NZ517331A (en) 1999-07-29 2004-02-27 Medarex Inc Human monoclonal antibodies to prostate specific membrane antigen and a transgenic mouse to produce the antibody
DE60037896D1 (en) 1999-07-29 2008-03-13 Medarex Inc HUMAN ANTIBODIES AGAINST HER2 / NEU
EP1212366B1 (en) 1999-07-30 2007-09-12 Medarex, Inc. Therapeutic compounds comprised of anti-fc receptor binding agents
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
CA2378646A1 (en) 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
AU6929100A (en) 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
CA2390412A1 (en) 1999-11-08 2001-05-17 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020028178A1 (en) 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US6380362B1 (en) 1999-12-23 2002-04-30 Genesis Research & Development Corporation Ltd. Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
EP1257197A4 (en) 2000-02-25 2008-07-16 Health Research Inc Method for transdermal sampling of analytes
JP2003528155A (en) 2000-03-24 2003-09-24 カイロン コーポレイション Method for treating non-Hodgkin's lymphoma using a combination of an antibody against CD20 and interleukin-2
CN1981868A (en) 2000-03-31 2007-06-20 拜奥根Idec公司 Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1939203B1 (en) 2000-04-25 2014-11-19 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform
EP1286692A4 (en) 2000-04-25 2004-11-17 Idec Pharma Corp Intrathecal administration of rituximab for treatment of central nervous system lymphomas
DK2223922T3 (en) 2000-04-25 2016-06-06 Icos Corp Inhibitors of HUMANPHOSPHATIDYL-inositol 3-KINASEDELTA
EP1284752A4 (en) 2000-04-26 2004-08-18 Elusys Therapeutics Inc Bispecific molecules and uses thereof
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
KR100643818B1 (en) 2000-05-08 2006-11-10 셀덱스 쎄라퓨틱스, 인크. Human monoclonal antibodies against dendritic cells
AU2001264946A1 (en) 2000-05-24 2001-12-03 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
AU6836301A (en) 2000-06-20 2002-01-02 Idec Pharma Corp Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
WO2001097843A2 (en) 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
MXPA02012867A (en) 2000-06-29 2003-09-05 Abbott Lab Dual specificity antibodies and methods of making and using.
KR20030031957A (en) 2000-07-12 2003-04-23 아이덱 파마슈티칼즈 코포레이션 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
AU2001272733A1 (en) 2000-07-19 2002-02-05 Orbotech Ltd. Apparatus and method for electrical testing of electrical circuits
US20020025317A1 (en) 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
AU2001282862A1 (en) 2000-07-24 2002-02-05 Florida State University Research Foundation Method and apparatus for removing minute particles from a surface
DE50112379D1 (en) 2000-08-11 2007-05-31 Univ Ruprecht Karls Heidelberg FV CONSTRUCTS WITH INFLUENCABLE AFFINITY TO A BONDING SUBSTANCE
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20020128448A1 (en) 2000-10-20 2002-09-12 Idec Pharmaceuticals Corporation Variant IgG3 Rituxan and therapeutic use thereof
CN101684158A (en) 2001-01-17 2010-03-31 特鲁比昂药品公司 Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
KR20030091978A (en) 2001-01-29 2003-12-03 아이덱 파마슈티칼즈 코포레이션 Modified antibodies and methods of use
CN100574803C (en) 2001-01-31 2009-12-30 拜奥根Idec公司 Use of immunomodulatory antibodies in the treatment of neoplastic diseases
NZ527977A (en) 2001-02-12 2005-10-28 Medarex Inc Human monoclonal antibodies to FC alpha receptor (CD89)
HUP0303428A2 (en) 2001-03-07 2004-01-28 Merck Patent Gmbh. Expression technology for proteins containing a hybrid isotype antibody moiety
US20050118164A1 (en) 2001-03-09 2005-06-02 William Herman Targeted ligands
ES2364816T3 (en) 2001-04-02 2011-09-14 Genentech, Inc. COMBINATION THERAPY.
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20030008923A1 (en) 2001-06-01 2003-01-09 Wyeth Antineoplastic combinations
WO2002100348A2 (en) 2001-06-13 2002-12-19 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
WO2002102312A2 (en) 2001-06-14 2002-12-27 Intermune, Inc. Combination therapy of gamma-interferon and b cell specific antibodies
US20020196854A1 (en) 2001-06-15 2002-12-26 Jongil Kim Fast video encoder using adaptive hierarchical video processing in a down-sampled domain
MXPA05000511A (en) * 2001-07-12 2005-09-30 Jefferson Foote Super humanized antibodies.
US20030026780A1 (en) 2001-07-18 2003-02-06 Hood Leroy E. Innate immunity mediated methods of treating pathological conditions
WO2003020906A2 (en) 2001-08-31 2003-03-13 Abmaxis, Inc. Multivalent protein conjugate with multiple ligand-binding domains of receptors
ES2276735T3 (en) 2001-09-14 2007-07-01 Affimed Therapeutics Ag SINGLE CHAIN MULTIMERIC FV ANTIBODIES IN TANDEM.
CA2461351C (en) 2001-09-26 2014-08-05 Ira H. Pastan Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
JP2005510470A (en) 2001-09-28 2005-04-21 エリューシス セラピューティクス，インコーポレーテッド Methods and compositions for the prevention, diagnosis and treatment of cancer using bispecific molecules
ATE423571T1 (en) 2001-10-12 2009-03-15 Schering Corp USE OF BISPECIFIC ANTIBODIES AGAINST AN ACTIVATIVE RECEPTOR FCEPSILONRI AND AGAINST AN INHIBITING RECEPTOR OX2RA (CD200RA) TO REGULATE IMMUNE RESPONSES
DE10156482A1 (en) 2001-11-12 2003-05-28 Gundram Jung Bispecific antibody molecule
ES2283368T3 (en) 2001-11-14 2007-11-01 Affimed Therapeutics Ag ANTI-CD19 AND ANTI-CD16 BIESPECIFIC ANTIBODIES AND USES OF THE SAME.
JP2005514030A (en) 2001-12-26 2005-05-19 イミューノメディクス、インコーポレイテッド Method for producing multispecific multivalent drugs from VH and VL domains
RU2004127458A (en) 2002-02-14 2005-10-27 Иммуномедикс, Инк. (Us) ANTI-CD20 ANTIBODIES, THEIR HYBRID PROTEINS AND WAYS OF THEIR USE
AU2003209446B2 (en) 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US8361464B2 (en) 2002-03-01 2013-01-29 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
US20030219436A1 (en) 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
CA2379586A1 (en) 2002-04-10 2003-10-10 William Herman Fluid targeted ligands
JP4518941B2 (en) 2002-04-26 2010-08-04 中外製薬株式会社 Agonist antibody screening method
AU2003247483A1 (en) 2002-05-30 2003-12-31 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
EP1600459A3 (en) 2002-06-28 2005-12-07 Domantis Limited Ligand
WO2004016750A2 (en) 2002-08-14 2004-02-26 Macrogenics, Inc. FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP1572131B1 (en) 2002-10-08 2016-07-06 Immunomedics, Inc. Antibody therapy
ES2533963T3 (en) 2002-10-10 2015-04-16 Merck Patent Gmbh Pharmaceutical compositions targeting Erb-B1 receptors
SI1551876T1 (en) 2002-10-16 2011-07-29 Purdue Pharma Lp Antibodies that bind cell-associated ca 125/0722p and methods of use thereof
KR20110017020A (en) 2002-10-17 2011-02-18 젠맵 에이/에스 Human monoclonal antibodies against CD20
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2004058191A2 (en) 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
ES2388280T3 (en) 2002-12-20 2012-10-11 Abbott Biotherapeutics Corp. Antibodies that react to GPR64 and use them
US7332303B2 (en) * 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
CA2414148A1 (en) 2002-12-30 2004-06-30 William Herman Targeted ligands
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
JP3803790B2 (en) 2003-02-17 2006-08-02 株式会社東北テクノアーチ Novel diabody-type bispecific antibody
CA2517054C (en) 2003-02-25 2016-05-10 Medinnova As Use of nucleic acids encoding antibody-like molecules for use in medical treatment
AR044388A1 (en) 2003-05-20 2005-09-07 Applied Molecular Evolution CD20 UNION MOLECULES
WO2005021710A2 (en) 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
CN1279056C (en) 2003-06-06 2006-10-11 马菁 Specific antibody of tumor-associated antigen SM5-1 and use thereof
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
EP1638510B1 (en) 2003-07-01 2015-09-02 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US6864837B2 (en) 2003-07-18 2005-03-08 Ems Technologies, Inc. Vertical electrical downtilt antenna
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005018671A1 (en) 2003-08-21 2005-03-03 Kyowa Hakko Kogyo Co., Ltd. Cancer metastasis inhibitor
ZA200601699B (en) 2003-10-16 2007-05-30 Micromet Ag Multispecific deimmunized CD3-binders
WO2005047337A1 (en) 2003-11-13 2005-05-26 Hanmi Pharmaceutical Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
AU2004309347B2 (en) 2003-12-19 2010-03-04 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
MXPA06007174A (en) 2003-12-22 2006-08-23 Novartis Ag BIOMARKERS TO DETERMINE THE SENSITIVITY OF PROLIFERATIVE DISEASES TO MTOR INHIBITORS.
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
WO2005070966A2 (en) 2004-01-16 2005-08-04 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
BRPI0507649A (en) 2004-02-16 2007-07-10 Micromet Ag bispecifically binding molecule, nucleic acid sequence, vector, process for the production of bispecifically binding molecule, composition, use of bispecifically binding molecule in the preparation of the pharmaceutical composition, and kit
AR047988A1 (en) 2004-03-11 2006-03-15 Wyeth Corp ANTI -OPLASTIC COMBINATIONS OF CCI-779 AND RITUXIMAB
JP4939397B2 (en) 2004-03-30 2012-05-23 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュ ユニバーシティ オブ エルサレム Bispecific antibodies for targeting cells involved in allergic reactions, and compositions and uses thereof
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
WO2006002438A2 (en) 2004-06-03 2006-01-05 Medarex, Inc. Human monoclonal antibodies to fc gamma receptor i (cd64)
CA2568336A1 (en) 2004-06-04 2005-12-22 Genentech, Inc. Method for treating lupus
EP1753455A2 (en) 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
WO2006020258A2 (en) 2004-07-17 2006-02-23 Imclone Systems Incorporated Novel tetravalent bispecific antibody
EP1978032A3 (en) 2004-07-22 2009-02-18 Erasmus University Medical Center Rotterdam Binding molecules
CA2578613A1 (en) 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
RU2411956C2 (en) 2004-10-05 2011-02-20 Дженентек, Инк. Method of treating vasculitis
ATE525400T1 (en) 2004-12-01 2011-10-15 Trion Pharma Gmbh USE OF TRIFUNCTIONAL ANTIBODIES FOR RISK REDUCTION OF GVHD IN ALLOGENETIC ANTI-TUMOR CELL THERAPY
JP2008523083A (en) 2004-12-08 2008-07-03 イムノメディクス， インコーポレイテッド Methods and compositions for immunotherapy and detection of inflammatory and immune dysregulated diseases, infectious diseases, pathological angiogenesis and cancer
FR2879204B1 (en) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement CYTOTOXIC ANTIBODY AGAINST HEMATOPOIETIC B-TYPE HEMATOPOIETIC PROLIFERATIONS
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
KR100616666B1 (en) 2005-01-27 2006-08-28 삼성전기주식회사 Method of forming guanidine group on carbon nanotube, Method of attaching carbon nanotube on which guanidine group is formed to a substrate, and carbon nanotube and substrate manufactured accordingly
DOP2006000029A (en) 2005-02-07 2006-08-15 Genentech Inc ANTIBODY VARIANTS AND USES THEREOF. (VARIATIONS OF AN ANTIBODY AND USES OF THE SAME)
CN101198698B (en) 2005-03-31 2014-03-19 中外制药株式会社 Process for production of polypeptide by regulation of assembly
AR053579A1 (en) 2005-04-15 2007-05-09 Genentech Inc TREATMENT OF INTESTINAL INFLAMMATORY DISEASE (IBD)
WO2006117782A2 (en) 2005-05-04 2006-11-09 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
KR20080031001A (en) 2005-06-02 2008-04-07 아스트라제네카 아베 Antibodies to CD20 and Their Uses
EP2295080A3 (en) 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
US20080279850A1 (en) 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
BRPI0614183A2 (en) 2005-07-25 2011-03-15 Trubion Pharmaceuticals Inc single-dose use of cd20-specific binding molecules
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP4641476B2 (en) 2005-09-15 2011-03-02 キヤノン株式会社 Probe array manufacturing equipment
WO2008053275A2 (en) * 2005-12-20 2008-05-08 Morphosys Ag Novel collection of hcdr3 regions and uses therefor
EA200870265A1 (en) 2006-02-15 2009-02-27 Имклоун Системз Инкорпорейтед FUNCTIONALLY ACTIVE ANTIBODIES
CN105837690A (en) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 Single-chain multivalent binding proteins with effector function
CA2663536A1 (en) 2006-10-24 2008-05-02 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
US7846434B2 (en) 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
AR065910A1 (en) 2007-04-02 2009-07-08 Genentech Inc FORECAST BIOLOGICAL MARKERS OF THE RESPONSE OF THE Rheumatoid ARTHRITIS TO THE ANTAGONISTS OF THE LYMPHOCYTES B
WO2008153636A1 (en) 2007-05-04 2008-12-18 Cellsignaling Technology, Inc. Phospho-specific antibodies to p13k regulatory subunit and uses thereof
PE20090215A1 (en) 2007-05-09 2009-03-30 Novartis Ag COMPOUNDS DERIVED FROM IMIDAZOPYRIDAZINE AS KINASE INHIBITORS
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
WO2008152387A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Quinazoline derivatives as pi3 kinase inhibitors
WO2008152394A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Pharmaceutical compounds
CN101679456B (en) 2007-06-12 2012-09-05 霍夫曼-拉罗奇有限公司 Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol 3-kinase
CN101990439A (en) * 2007-07-06 2011-03-23 特鲁比昂药品公司 Binding peptides having a c-terminally disposed specific binding domain
PE20140196A1 (en) 2007-08-09 2014-03-19 Boehringer Ingelheim Int ANTI-CD37 ANTIBODIES
AU2008298948B2 (en) 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
EP2217590A4 (en) 2007-09-17 2011-12-14 Glaxosmithkline Llc Pyridopyrimidine derivatives as pi3 kinase inhibitors
ES2399774T3 (en) 2007-09-24 2013-04-03 Genentech, Inc. Thiazolopyrimidine compounds PI3K inhibitors and methods of use
EP2193133B1 (en) 2007-09-27 2015-08-19 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Imidazolothiadiazoles for use as protein kinase inhibitors
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
DK2209786T3 (en) 2007-10-05 2013-06-03 Verastem Inc PYRIMIDINE-SUBSTITUTED PURINDER DERIVATIVES
WO2009045174A1 (en) 2007-10-05 2009-04-09 S*Bio Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
CA2702838A1 (en) 2007-10-16 2009-04-23 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors
JP2011500823A (en) 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pyridosulfonamide derivatives as PI3 kinase inhibitors
GB0721095D0 (en) 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
EP2215090B1 (en) 2007-10-26 2015-03-04 F. Hoffmann-La Roche AG Purine derivatives useful as pi3 kinase inhibitors
US7951832B2 (en) 2007-10-31 2011-05-31 Burnham Institute For Medical Research Pyrazole derivatives as kinase inhibitors
WO2009058361A1 (en) 2007-10-31 2009-05-07 Dynavax Technologies Corp. Inhibition of type i ifn production
GEP20125635B (en) 2007-11-13 2012-09-10 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2009066084A1 (en) 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
WO2009070524A1 (en) 2007-11-27 2009-06-04 Wyeth Pyrrolo[3,2-d]pyrimidine compounds and their use as pi3 kinase and mtor kinase inhibitors
EP2222674B8 (en) 2007-11-27 2016-01-06 Cellzome Limited Amino triazoles as pi3k inhibitors
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
PT2132228E (en) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
WO2010057047A1 (en) 2008-11-13 2010-05-20 Trubion Pharmaceutics, Inc. Cd37 immunotherapeutic combination therapies and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050136049A1 (en) * 2001-01-17 2005-06-23 Ledbetter Jeffrey A. Binding constructs and methods for use thereof

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Trubion Pharmaceuticals Inc. Presents Positive Data On First Pre-Clinical Product Candidates At American Society of Hematology (ASH)", BIOSPACE, 8 December 2003 (2003-12-08), San Diego, pages 1 - 3, XP002420826, Retrieved from the Internet <URL:http://www.biospace.com/news_story.aspx?StoryID=14573420&full=1> [retrieved on 20070215] *
BARONE D ET AL: "Prolonged depletion of circulating B cells in cynomolgus monkeys after a single dose of TRU-015, a novel CD20 directed therapeutic", ANNALS OF THE RHEUMATIC DISEASES, vol. 64, no. Suppl. 3, July 2005 (2005-07-01), & ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY; VIENNA, AUSTRIA; JUNE 08 11, 2005, pages 159 - 160, XP008075207, ISSN: 0003-4967 *
BUCHSBAUM D J ET AL: "Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.", CANCER RESEARCH 1 DEC 1992, vol. 52, no. 23, 1 December 1992 (1992-12-01), pages 6476 - 6481, XP008075262, ISSN: 0008-5472 *
D. S. BARONE, C. NILSSON, J. LEDBETTER, M. HAYDEN-LEDBETTER AND K. MOHLER: "Efficacy of SMIP-016, a novel CD37-directed biologic therapy, in human NHL tumor xenograft models", JOURNAL OF CLINICAL ONCOLOGY, vol. 24, no. 18s, 20 June 2006 (2006-06-20), USA, pages 1, XP002420829, Retrieved from the Internet <URL:http://meeting.jco.org/cgi/gca?sendit=Get+All+Checked+Abstract%28s%29&SEARCHID=1&FULLTEXT=smip&VOLUME=24&ISSUE=18_suppl&FIRSTINDEX=0&hits=10&RESULTFORMAT=&gca=ascomtg%3B24%2F18_suppl%2F2565> [retrieved on 20070216] *
DAVIES JAMIE: "American society of hematology-45th annual meeting and exposition: hematological malignancies.", IDRUGS : THE INVESTIGATIONAL DRUGS JOURNAL JAN 2004, vol. 7, no. 1, January 2004 (2004-01-01), pages 1 - 3, XP002420827, ISSN: 1369-7056 *
HAYDEN-LEDBETTER MARTHA ET AL: "Induction of apoptosis in B lymphoma cell lines by CytoxB37G, a small modular immunopharmaceutical (SMIP) that binds CD37.", BLOOD, vol. 102, no. 11, 16 November 2003 (2003-11-16), & 45TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 06-09, 2003, pages 432a, XP002420825, ISSN: 0006-4971 *
KIESEL S ET AL: "REMOVAL OF CELLS FROM A MALIGNANT B-CELL LINE FROM BONE MARROW WITHIMMUNOMAGNETIC BEADS AND WITH COMPLEMENT AND IMMUNOGLOBULIN SWITCH VARIANT MEDIATED CYTOLYSIS", LEUKEMIA RESEARCH, NEW YORK,NY, US, vol. 11, no. 12, 1987, pages 1119 - 1125, XP000570474, ISSN: 0145-2126 *
LEANDRO M J ET AL: "Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion", ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 61, no. 10, October 2002 (2002-10-01), pages 883 - 888, XP002348932, ISSN: 0003-4967 *
PRESS O W ET AL: "RADIOLABELED-ANTIBODY THERAPY OF B-CELL LYMPHOMA WITH AUTOLOGOUS BONE MARROW SUPPORT", NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, vol. 329, no. 17, 21 October 1993 (1993-10-21), pages 1219 - 1224, XP008075157, ISSN: 0028-4793 *
PRESS O W ET AL: "TREATMENT OF REFRACTORY NON-HODGKIN'S LYMPHOMA WITH RADIOLABELED MB-1 (ANTI-CD37) ANTIBODY", JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, NEW YORK, NY, US, vol. 7, no. 8, August 1989 (1989-08-01), pages 1027 - 1038, XP002936241, ISSN: 0732-183X *
REFF M E ET AL: "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 83, no. 2, 15 January 1994 (1994-01-15), pages 435 - 445, XP002112549, ISSN: 0006-4971 *
ZHAO XIAOBIN B ET AL: "Novel anti-CD37 small modular immunopharmaceutical (SMIP) induces B-cell-specific, caspase-independent apoptosis in human CLL cells.", BLOOD, vol. 104, no. 11, Part 1, November 2004 (2004-11-01), & 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, pages 689A, XP002420828, ISSN: 0006-4971 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12577316B2 (en) 2017-03-31 2026-03-17 Genmab Holding B.V. Methods of use of anti-CD37 antibodies, monoclonal anti-CD37 antibodies

Also Published As

Publication number Publication date
KR101251157B1 (en) 2013-04-10
RS53318B (en) 2014-10-31
NZ606294A (en) 2014-09-26
IL188345A (en) 2015-04-30
PT1912675E (en) 2014-05-09
EP2295080A3 (en) 2011-06-22
EP2298815A1 (en) 2011-03-23
ES2460517T3 (en) 2014-05-13
JP2012165760A (en) 2012-09-06
JP2009502171A (en) 2009-01-29
BRPI0614184A2 (en) 2011-03-15
NZ564764A (en) 2011-08-26
UA97469C2 (en) 2012-02-27
HRP20150591T1 (en) 2015-07-31
DK1912675T3 (en) 2014-03-24
BRPI0614184A8 (en) 2017-10-10
SI2298815T1 (en) 2015-08-31
EP1912675A2 (en) 2008-04-23
CA2616395A1 (en) 2007-02-01
JP5740076B2 (en) 2015-06-24
US20090214539A1 (en) 2009-08-27
SI1912675T1 (en) 2014-07-31
NI200800032A (en) 2009-03-23
AU2006272555A1 (en) 2007-02-01
PL2298815T3 (en) 2015-08-31
PT2298815E (en) 2015-07-16
US20140010813A1 (en) 2014-01-09
SG155912A1 (en) 2009-10-29
CN105012953B (en) 2018-06-22
ECSP088133A (en) 2008-02-20
RU2423381C2 (en) 2011-07-10
EP2586798A3 (en) 2013-08-07
US20140072562A1 (en) 2014-03-13
KR20080032192A (en) 2008-04-14
US20190290755A1 (en) 2019-09-26
AU2006272555B2 (en) 2012-03-08
HUE026303T2 (en) 2016-06-28
EP1912675B1 (en) 2014-02-12
US20070059306A1 (en) 2007-03-15
RU2008106893A (en) 2009-09-10
DK2298815T3 (en) 2015-06-15
EP2295080A2 (en) 2011-03-16
CN101282745B (en) 2015-04-29
US10307481B2 (en) 2019-06-04
ES2539250T3 (en) 2015-06-29
ZA200800692B (en) 2011-10-26
CA2616395C (en) 2016-10-04
WO2007014278A2 (en) 2007-02-01
CN101282745A (en) 2008-10-08
NZ594275A (en) 2013-04-26
IL188345A0 (en) 2008-04-13
US20140004117A1 (en) 2014-01-02
EP2298815B1 (en) 2015-03-11
US10143748B2 (en) 2018-12-04
SG10201403526YA (en) 2014-10-30
NO20080217L (en) 2008-04-16
HRP20140338T1 (en) 2014-06-20
IL237881A0 (en) 2015-05-31
RS54088B1 (en) 2015-10-30
US20130266561A1 (en) 2013-10-10
PL1912675T3 (en) 2014-10-31
EP2586798A2 (en) 2013-05-01
CO6160337A2 (en) 2010-05-20
CR9761A (en) 2008-05-21
CN105012953A (en) 2015-11-04
HK1155761A1 (en) 2012-05-25
HK1125288A1 (en) 2009-08-07
JP2014196350A (en) 2014-10-16
HK1115820A1 (en) 2008-12-12

Similar Documents

Publication Publication Date Title
EP2586798A3 (en) B-cell reduction using CD37-specific and CD20-specific binding molecules
WO2007014238A8 (en) Single dose use of cd20-specific binding molecules
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
PL1761266T3 (en) Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
WO2007140002A3 (en) Method for treating non-hodgkin&#39;s lymphoma
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
IL233634A0 (en) Methods, compositions, and kits for the treatment of medical conditions
WO2006119329A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
WO2008029169A3 (en) Method of treating respiratory disorders
WO2007059226A3 (en) Photoactivatable antimicrobial agents
EP1888143B8 (en) Disposable cartridge, and apparatus for the blood treatment
WO2007051785A3 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
TWI372047B (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
WO2006078336A3 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2005091754A3 (en) Novel cyclopentenedione antifungal compounds and methods for their use
GB0518916D0 (en) Treating commodities against unwanted biological activity
WO2005077018A3 (en) Methods of treating skin disorders
WO2006055404A3 (en) Compounds for targeting mechanisms implicated in the progression of stroke
WO2008008507A3 (en) Methods of treatment of diabetes
GB0707437D0 (en) Methods and compositions for treating hyperglycemic, hyperlipidemic, or hyperinsulinemic disorders
AP2005003270A0 (en) Composition for the treatment of humans.
AU2005903146A0 (en) Methods for the diagnosis and treatment of epilepsy
AU2005906446A0 (en) Methods for the diagnosis and treatment of epilepsy

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680027227.9

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2006272555

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 564764

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 188345

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 197/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 08003675

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 12008500135

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2616395

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006788565

Country of ref document: EP

Ref document number: 2008010120

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/001131

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008524109

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006272555

Country of ref document: AU

Date of ref document: 20060725

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087003703

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: CR2008-009761

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2008106893

Country of ref document: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06788565

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: CR2008-009761

Country of ref document: CR

ENP Entry into the national phase

Ref document number: PI0614184

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080125

WWE Wipo information: entry into national phase

Ref document number: P-2014/0232

Country of ref document: RS

WWG Wipo information: grant in national office

Ref document number: CR2008-009761

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 237881

Country of ref document: IL